Gottlieb Scott

Director Gottlieb Scott bought 200 ILMN shares at $117.81; stock down 24.4% from 52-week high, now trading $116.38.

Gottlieb Scott, a Director, purchased 200 shares of Illumina at $117.81 on 2026-02-09, increasing his holdings to 12,723 shares. The purchase price was approximately $1.43 above the current market price of $116.38, placing the transaction near recent lows following a steep 20% decline over the past 30 days. ILMN trades 24.4% below its 52-week high, though it remains profitable with $150.0M net income on $1.1B quarterly revenue. Scott's prior buy at this ticker on 2025-11-03 delivered a 90-day return of +18.6%, establishing a pattern of well-timed purchases at ILMN. The company's full-year net income turned negative despite current-quarter profitability, signaling operational headwinds that warrant investor attention. The insider's timing at a depressed price relative to recent history, combined with his prior success at this ticker, merits monitoring of the company's trajectory.

Director Gottlieb Scott buys 500 ILMN shares at $122.13; cross-ticker track record shows weak 30d returns, poor 90d win rate at 25%.

Gottlieb Scott purchased 500 shares of ILLUMINA at $122.13 on 2025-11-03, increasing his holdings from 12,023 to 12,523 shares. The stock has since risen 21.2% over 30 days and 28.2% over 90 days, trading at $122.44 (current). However, Scott's cross-ticker track record across his open-market history shows limited predictive value: his 4 prior buys averaged +0.5% 30-day returns with only a 25.00% win rate over 90 days, while his 9 prior sells averaged -4.7% 30-day returns (though +41.1% over 90 days, a poorly-timed outcome that suggests he exited before gains materialized). ILLUMINA itself faces headwinds: revenue declined 2.9% year-over-year, the company posted a negative net income for its most recent full fiscal year, and the stock trades at a P/E of 26.62 while down 21.1% from its 52-week high despite the recent rally. The transaction is modest in absolute terms ($61.1K) and represents a 4.2% increase in Scott's stake, offering limited insight into board-level conviction given his mixed prior execution across tickers.

Director Gottlieb Scott sold 27,837 shares (27.8K) of TEM for $1,314,153.74 across 4 transactions at blended avg $47.21 on 2025-04-01

Scott executed four separate sales totaling 27,837 shares for $1,314,153.74 on April 1, 2025, reducing his holdings by 45.9% from 60,676 shares to 32,839 shares. The sales occurred at prices ranging from $46.07 to $48.69, with a blended average of $47.21, at a point when the stock was trading 48.4% below its 52-week high of $89.44 and had declined 12.4% over the prior 30 days. This sale follows a pattern of repeated transactions by Scott at this ticker: he conducted five prior sales at TEM, all on 2025-03-17, though these recent outcomes are not yet measurable. The company remains unprofitable (net income of $-75,840,000.00 on revenue of $180,929,000.00 in the latest quarter) despite posting annual revenue growth of 30.4%, creating a disconnect between growth and profitability. The scale and timing of this liquidation—coinciding with recent stock weakness and the company's ongoing operating losses—merit attention as a data point in evaluating TEM's near-term investor positioning.

Director Gottlieb Scott sells 27,838 shares of Tempus AI for $1,359,988.91 at blended average $48.85

Gottlieb Scott, a director at Tempus AI, executed 5 separate sales on 2025-03-17 totaling 27,838 shares for $1,359,988.91, reducing his holdings by 31.5% from 88,514 shares to 60,676 shares. The sales occurred across a narrow price range ($46.59–$50.45), with the blended average of $48.85 now trading 0.8% above the current price of $48.03. The company is currently unprofitable with net income of $-75,840,000.00 against $180,929,000.00 in quarterly revenue, though it posted 30.4% annual revenue growth. Scott's cross-ticker track record shows a 25.00% 90-day win rate with an average 90-day return of -4.3%, providing limited basis for timing assessment at this ticker. The magnitude of the reduction—removing nearly one-third of his holdings in a single day—stands out against the backdrop of the stock's 46.3% decline from its 52-week high.

Director Scott Gottlieb buys 1,000 PFE shares at $28.24; stock down 7.0% in 90 days, 1 of 3 prior buys at ticker showed positive 90d return

Gottlieb purchased 1,000 shares at $28.24, increasing his holdings to 10,000 shares (+11.1% vs pre-transaction holdings). Pfizer's stock has declined 7.0% over 90 days and is currently down 9.8% from its 52-week high of $31.39. His cross-ticker track record shows mixed results: 3 prior buys averaged +3.0% over 30 days but -4.0% over 90 days, with only a 33.33% win rate. At Pfizer specifically, his prior three purchases had inconsistent outcomes: one delivered +8.4% in 30 days and +6.3% in 90 days, while the other two posted negative 90-day returns of -9.2% and -8.9%, with only 1 of 3 prior PFE buys showing positive 90-day returns. The purchase occurs against a backdrop of significant fundamental headwinds—annual revenue contracted 41.7% year-over-year and net income stands at only $41.0M on quarterly revenue of $13.3B—leaving the timing and conviction signal of this transaction ambiguous.